Disclosed is a patch in which degradation of asenapine or a pharmaceutically acceptable salt thereof is inhibited. The patch comprises an adhesive layer on a base, wherein the adhesive layer contains an adhesive base, asenapine or a pharmaceutically acceptable salt thereof, and at least one basic amino acid selected from the group consisting of lysine, arginine and histidine, or a pharmaceutically acceptable salt of said basic amino acid.

Anhydrous hydrocolloid matrices contain one or more encapsulated therapeutic agents, including an acne agent and/or skin conditioning agent. The anhydrous hydrocolloid matrices are used as acne treatment dressings alone or in a laminate with a water-impermeable or semi-water impermeable backing and a release liner. The anhydrous hydrocolloid matrices are made using a premix of viscosity modifiers and hydrocarbon emollients and the one or more therapeutic agents, which are mixed via high shear mixing to form the premix. The resulting anhydrous hydrocolloid matrices include the one or more therapeutic agents which are encapsulated and homogeneously distributed therein.

Disclosed herein is a two-part processing method that involves the extraction and transdermal delivery of psilocybin active components.

Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed.

##STR00001##

The present invention provides the following compounds having anti-viral activity.

##STR00001## A.sup.1 is CR.sup.1AR.sup.1B, S or O; A.sup.2 is CR.sup.2AR.sup.2B, S or O; A.sup.3 is CR.sup.3AR.sup.3B, S or O; A.sup.4 is CR.sup.4AR.sup.4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A.sup.1, A.sup.2, A.sup.3, A.sup.4, nitrogen atom adjacent to A.sup.1 and carbon atom adjacent to A.sup.1, is 1 or 2; R.sup.1A and R.sup.1B are each independently hydrogen, halogen, alkyl, or the like; R.sup.2A and R.sup.2B are each independently hydrogen, halogen, alkyl, or the like; R.sup.3A and R.sup.3B are each independently hydrogen, halogen, alkyl, or the like; R.sup.4A and R.sup.4B are each independently hydrogen, halogen, alkyl, or the like; R.sup.3A and R.sup.3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH.sub.2, S or O; R.sup.1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.

Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and C) optionally an additional skin contact layer.

A method of selecting a skin barrier system suitable for infants and young children is disclosed.

Flexible packages, transdermal drug delivery devices, and methods for fabricating packages are provided. An exemplary flexible package includes a chemical and moisture resistant layer formed from poly(chlorotrifluoroethylene-co-vinylidene fluoride) (“P(CTFE-co-VDF)”) copolymer. Further, the exemplary flexible package includes a substance to be delivered. The substance is applied to or enclosed by the chemical and moisture resistant layer.

[Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult. [Solution] A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2000 g/50 mm and of biaxially-oriented stretch cloth.

The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.